Camurus’ Full Year Report 2025

Camurus reported FY2025 revenues of SEK 2,265m, up 21% YoY, with profit before tax rising 69% to SEK 933m and year-end cash of SEK 3.7bn; full-year product sales were SEK 1,752m and royalties jumped 87% to SEK 396m. Q4 was weaker—total revenues fell 16% to SEK 464m and product sales declined 27%—primarily due to a SEK 93m one-time inventory repurchase tied to a UK distribution change and FX headwinds. Management resubmitted an NDA for Oclaiz™, launched Oczyesa® in Germany, reported positive Phase 1b results for a monthly semaglutide depot (CAM2056), and announced a Gubra collaboration; 2026 guidance targets SEK 2.6–2.9bn revenue and SEK 0.9–1.2bn operating result, implying ~21% midpoint growth versus 2025.

Analysis

Market structure: Camurus (Nasdaq Stockholm: CAMX) is shifting from a product-sales story to a royalties-and-platform optionality story — royalties jumped 87% y/y to SEK 396m while product sales grew only 6% in 2025. Guidance midpoint implies ~+21% revenue growth for 2026 (SEK 2.75bn), which combined with SEK 3.7bn cash (≈1.6x 2025 revenues) reduces near-term financing risk and increases downside resilience; successful commercial rollouts in Germany and partner markets will meaningfully expand recurring royalty cashflows over 12–24 months.

Risk assessment: Principal tail risks are FDA refusal of Oclaiz (resubmitted) and competitive displacement of depot GLP‑1 by incumbents; an FDA complete response letter would likely compress NAV by 30–50% near term. Hidden dependency: royalties and regulatory timing rely on partners’ commercial execution and FX (Q4 showed FX headwinds); catalyst sequencing — FDA decision, CAM2056 Phase 2/3 readouts, and continued Buvidal/Brixadi uptake — will drive binary moves over 3–12 months.

Trade implications: Tactical long exposure to CAMX is asymmetric given cash buffer and multiple near-term positive catalysts; use limited-duration call spreads to capture upside around regulatory/readout windows while capping premium. Cross-asset: limited credit impact (strong cash) but SEK-sensitive equity moves — a large positive approval would attract EUR/USD inflows, tightening SEK; volatility in options should rise into FDA/readouts, favoring debit spreads over naked longs.

Contrarian angles: Consensus likely underweights the optionality in monthly semaglutide (CAM2056) — positive differentiation vs weekly products could create licensing or acquisition M&A interest, not priced into current market caps. Conversely, market may under-price execution risk in partner-led royalties after the UK inventory repurchase (SEK 93m); if CAMX proves repeatable royalty growth (+20–30% CAGR next 2 years), re-rate potential is material (30–60% upside), but absent approvals upside is limited.

Key Decisions for Investors

• Establish a 2–3% long position in CAMX (Nasdaq Stockholm: CAMX) on pullback of ≥8% from current levels or on a close above next resistance; target +40% in 6–12 months if Oclaiz approval or clear CAM2056 Phase‑2 data, set hard stop-loss at −20% to control binary regulatory risk.
• Buy a 9–15 month call spread on CAMX sized to 1–2% of portfolio (buy ATM call, sell a call ~+40–50% strike) to play FDA/readout catalysts while capping premium; roll or take profits if spread reaches 50–80% of max value or if negative regulatory news arrives.
• Implement a relative-value pair: long CAMX (2% gross) vs short a small-cap European specialty-pharma name with weak cash and no 12‑month catalysts (example short candidate for further DD: ORX.ST (Orexo) size 2% gross). This hedges sector beta while isolating Camurus-specific optionality.
• Reduce large-cap GLP‑1 concentrated exposure (e.g., NVO or LLY) by 1–2% and reallocate into CAMX/long-depot-technology exposure to capture asymmetric upside from long-acting semaglutide optionality; re-evaluate after FDA PDUFA window or within 60 days of any formal FDA timeline announcement.